Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Folate receptor-beta expression as a diagnostic target in human & rodent nonalcoholic steatohepatitis.

Lake AD, Hardwick RN, Leamon CP, Low PS, Cherrington NJ.

Toxicol Appl Pharmacol. 2019 Apr 1;368:49-54. doi: 10.1016/j.taap.2019.02.009. Epub 2019 Feb 19.

PMID:
30794826
2.

Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease.

Clarke JD, Novak P, Lake AD, Hardwick RN, Cherrington NJ.

Liver Int. 2017 Jul;37(7):1074-1081. doi: 10.1111/liv.13362. Epub 2017 Feb 7.

3.

3D bioengineered tissues: From advancements in in vitro safety to new horizons in disease modeling.

Hardwick RN, Viergever C, Chen AE, Nguyen DG.

Clin Pharmacol Ther. 2017 Apr;101(4):453-457. doi: 10.1002/cpt.569. Epub 2017 Feb 7.

PMID:
27864923
4.

Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis.

Canet MJ, Merrell MD, Hardwick RN, Bataille AM, Campion SN, Ferreira DW, Xanthakos SA, Manautou JE, A-Kader HH, Erickson RP, Cherrington NJ.

Drug Metab Dispos. 2015 Jun;43(6):829-35. doi: 10.1124/dmd.114.062703. Epub 2015 Mar 18.

5.

Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis.

Canet MJ, Hardwick RN, Lake AD, Dzierlenga AL, Clarke JD, Goedken MJ, Cherrington NJ.

Drug Metab Dispos. 2015 Feb;43(2):266-72. doi: 10.1124/dmd.114.060574. Epub 2014 Dec 8.

6.

Systems level metabolic phenotype of methotrexate administration in the context of non-alcoholic steatohepatitis in the rat.

Kyriakides M, Hardwick RN, Jin Z, Goedken MJ, Holmes E, Cherrington NJ, Coen M.

Toxicol Sci. 2014 Nov;142(1):105-16. doi: 10.1093/toxsci/kfu160. Epub 2014 Aug 21.

7.

Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis.

Hardwick RN, Clarke JD, Lake AD, Canet MJ, Anumol T, Street SM, Merrell MD, Goedken MJ, Snyder SA, Cherrington NJ.

Toxicol Sci. 2014 Nov;142(1):45-55. doi: 10.1093/toxsci/kfu156. Epub 2014 Jul 31.

8.

Synergistic interaction between genetics and disease on pravastatin disposition.

Clarke JD, Hardwick RN, Lake AD, Lickteig AJ, Goedken MJ, Klaassen CD, Cherrington NJ.

J Hepatol. 2014 Jul;61(1):139-47. doi: 10.1016/j.jhep.2014.02.021. Epub 2014 Mar 5.

9.
10.

Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression.

Clarke JD, Hardwick RN, Lake AD, Canet MJ, Cherrington NJ.

J Pharmacol Exp Ther. 2014 Mar;348(3):452-8. doi: 10.1124/jpet.113.211284. Epub 2014 Jan 8.

11.

Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models.

Canet MJ, Hardwick RN, Lake AD, Dzierlenga AL, Clarke JD, Cherrington NJ.

Drug Metab Dispos. 2014 Apr;42(4):586-95. doi: 10.1124/dmd.113.055996. Epub 2014 Jan 2.

12.

Role of hepatic efflux transporters in regulating systemic and hepatocyte exposure to xenobiotics.

Pfeifer ND, Hardwick RN, Brouwer KL.

Annu Rev Pharmacol Toxicol. 2014;54:509-35. doi: 10.1146/annurev-pharmtox-011613-140021. Epub 2013 Oct 23. Review.

PMID:
24160696
13.

The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease.

Lake AD, Novak P, Hardwick RN, Flores-Keown B, Zhao F, Klimecki WT, Cherrington NJ.

Toxicol Sci. 2014 Jan;137(1):26-35. doi: 10.1093/toxsci/kft230. Epub 2013 Oct 4.

14.

Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver.

Pfeifer ND, Bridges AS, Ferslew BC, Hardwick RN, Brouwer KL.

J Pharmacol Exp Ther. 2013 Dec;347(3):737-45. doi: 10.1124/jpet.113.208314. Epub 2013 Sep 30.

15.

Basolateral uptake of nucleosides by Sertoli cells is mediated primarily by equilibrative nucleoside transporter 1.

Klein DM, Evans KK, Hardwick RN, Dantzler WH, Wright SH, Cherrington NJ.

J Pharmacol Exp Ther. 2013 Jul;346(1):121-9. doi: 10.1124/jpet.113.203265. Epub 2013 May 2.

16.

Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease.

Hardwick RN, Ferreira DW, More VR, Lake AD, Lu Z, Manautou JE, Slitt AL, Cherrington NJ.

Drug Metab Dispos. 2013 Mar;41(3):554-61. doi: 10.1124/dmd.112.048439. Epub 2012 Dec 7.

17.

The hepatic bile acid transporters Ntcp and Mrp2 are downregulated in experimental necrotizing enterocolitis.

Cherrington NJ, Estrada TE, Frisk HA, Canet MJ, Hardwick RN, Dvorak B, Lux K, Halpern MD.

Am J Physiol Gastrointest Liver Physiol. 2013 Jan 1;304(1):G48-56. doi: 10.1152/ajpgi.00317.2012. Epub 2012 Nov 1.

18.

Altered arsenic disposition in experimental nonalcoholic fatty liver disease.

Canet MJ, Hardwick RN, Lake AD, Kopplin MJ, Scheffer GL, Klimecki WT, Gandolfi AJ, Cherrington NJ.

Drug Metab Dispos. 2012 Sep;40(9):1817-24. doi: 10.1124/dmd.112.046177. Epub 2012 Jun 14.

19.

Measuring altered disposition of xenobiotics in experimental models of liver disease.

Hardwick RN, Cherrington NJ.

Curr Protoc Toxicol. 2012 May;Chapter 23:Unit 23.1.. doi: 10.1002/0471140856.tx2301s52.

PMID:
22549269
20.

Arsenite activates NFκB through induction of C-reactive protein.

Druwe IL, Sollome JJ, Sanchez-Soria P, Hardwick RN, Camenisch TD, Vaillancourt RR.

Toxicol Appl Pharmacol. 2012 Jun 15;261(3):263-70. doi: 10.1016/j.taap.2012.04.005. Epub 2012 Apr 12.

21.

Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.

Hardwick RN, Fisher CD, Street SM, Canet MJ, Cherrington NJ.

Drug Metab Dispos. 2012 Mar;40(3):450-60. doi: 10.1124/dmd.111.041095. Epub 2011 Nov 23.

22.

Genetic variation in the mouse model of Niemann Pick C1 affects female, as well as male, adiposity, and hepatic bile transporters but has indeterminate effects on caveolae.

Jelinek DA, Maghsoodi B, Borbon IA, Hardwick RN, Cherrington NJ, Erickson RP.

Gene. 2012 Jan 10;491(2):128-34. doi: 10.1016/j.gene.2011.10.010. Epub 2011 Oct 14.

23.

Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease.

Hardwick RN, Fisher CD, Canet MJ, Scheffer GL, Cherrington NJ.

Drug Metab Dispos. 2011 Dec;39(12):2395-402. doi: 10.1124/dmd.111.041012. Epub 2011 Aug 30.

24.

Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease.

Lake AD, Novak P, Fisher CD, Jackson JP, Hardwick RN, Billheimer DD, Klimecki WT, Cherrington NJ.

Drug Metab Dispos. 2011 Oct;39(10):1954-60. doi: 10.1124/dmd.111.040592. Epub 2011 Jul 7.

25.

Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease.

Hardwick RN, Fisher CD, Canet MJ, Lake AD, Cherrington NJ.

Drug Metab Dispos. 2010 Dec;38(12):2293-301. doi: 10.1124/dmd.110.035006. Epub 2010 Aug 30.

Supplemental Content

Loading ...
Support Center